Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Posted: December 25, 2024 at 2:51 am

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function

Read more here:
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Related Posts